As of 2026-05-13, the Relative Valuation of Kalvista Pharmaceuticals Inc (KALV) is (21.18) USD. This relative valuation is based on P/E multiples. With the latest stock price at 26.73 USD, the upside of Kalvista Pharmaceuticals Inc based on Relative Valuation is -179.2%.
The range of the Relative Valuation is (18.68) - (23.71) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.9x - 20.4x | 18.4x |
| Forward P/E multiples | 14.4x - 20.2x | 17.7x |
| Fair Price | (18.68) - (23.71) | (21.18) |
| Upside | -169.9% - -188.7% | -179.2% |
| Date | P/E |
| 2026-05-12 | -22.75 |
| 2026-05-11 | -22.73 |
| 2026-05-08 | -22.75 |
| 2026-05-07 | -22.74 |
| 2026-05-06 | -22.74 |
| 2026-05-05 | -22.73 |
| 2026-05-04 | -22.69 |
| 2026-05-01 | -22.68 |
| 2026-04-30 | -22.69 |
| 2026-04-29 | -22.70 |
| 2026-04-28 | -16.37 |
| 2026-04-27 | -16.31 |
| 2026-04-24 | -16.71 |
| 2026-04-23 | -16.24 |
| 2026-04-22 | -16.65 |
| 2026-04-21 | -16.53 |
| 2026-04-20 | -17.76 |
| 2026-04-17 | -17.43 |
| 2026-04-16 | -16.65 |
| 2026-04-15 | -17.75 |
| 2026-04-14 | -17.27 |
| 2026-04-13 | -16.67 |
| 2026-04-10 | -16.50 |
| 2026-04-09 | -16.98 |
| 2026-04-08 | -16.40 |
| 2026-04-07 | -17.12 |
| 2026-04-06 | -17.18 |
| 2026-04-02 | -16.93 |
| 2026-04-01 | -16.82 |
| 2026-03-31 | -17.13 |
| 2026-03-30 | -15.62 |
| 2026-03-27 | -16.45 |
| 2026-03-26 | -16.13 |
| 2026-03-25 | -14.59 |
| 2026-03-24 | -14.01 |
| 2026-03-23 | -14.13 |
| 2026-03-20 | -14.47 |
| 2026-03-19 | -13.98 |
| 2026-03-18 | -13.18 |
| 2026-03-17 | -14.09 |
| 2026-03-16 | -14.31 |
| 2026-03-13 | -14.42 |
| 2026-03-12 | -14.79 |
| 2026-03-11 | -15.52 |
| 2026-03-10 | -15.69 |
| 2026-03-09 | -14.72 |
| 2026-03-06 | -13.81 |
| 2026-03-05 | -13.79 |
| 2026-03-04 | -13.93 |
| 2026-03-03 | -13.28 |